Oric Pharmaceuticals Inc
$ 7.82
3.71%
11 Jun - close price
- Market Cap 780,522,000 USD
- Current Price $ 7.82
- High / Low $ 7.86 / 7.46
- Stock P/E N/A
- Book Value 4.02
- EPS -1.39
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -0.43 %
- 52 Week High 14.93
- 52 Week Low 7.23
About
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers. The company is headquartered in South San Francisco, California.
Analyst Target Price
$20.36
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-04 | 2026-02-23 | 2025-11-13 | 2025-08-12 | 2025-05-05 | 2025-02-18 | 2024-11-12 | 2024-08-12 | 2024-05-06 | 2024-03-11 | 2023-11-06 | 2023-08-10 |
| Reported EPS | -0.34 | -0.3 | -0.33 | -0.47 | -0.42 | -0.51 | -0.49 | -0.45 | -0.37 | -0.49 | -0.44 | -0.5 |
| Estimated EPS | -0.3837 | -0.3669 | -0.4 | -0.44 | -0.44 | -0.5084 | -0.4717 | -0.41 | -0.44 | -0.49 | -0.46 | -0.57 |
| Surprise | 0.0437 | 0.0669 | 0.07 | -0.03 | 0.02 | -0.0016 | -0.0183 | -0.04 | 0.07 | 0 | 0.02 | 0.07 |
| Surprise Percentage | 11.3891% | 18.2339% | 17.5% | -6.8182% | 4.5455% | -0.3147% | -3.8796% | -9.7561% | 15.9091% | 0% | 4.3478% | 12.2807% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ORIC
2026-06-11 20:40:49
Stifel analyst Laura Prendergast has reinitiated coverage on Oric Pharmaceuticals (ORIC) with a Buy rating and a $14 price target, ahead of a planned Phase 3 clinical trial for its lead drug candidate, rinzimetostat. The drug targets metastatic castration-resistant prostate cancer, and the trial is significant for the company's future. While ORIC has a low GF Score™ of 35 due to profitability challenges, it boasts strong financial health to support its development pipeline.
2026-06-10 11:09:53
ORIC Pharmaceuticals is strategically positioning itself for growth in the expanding oncology market by focusing on therapies that address treatment resistance. The company's pipeline includes rinzimetostat for prostate cancer and enozertinib for non-small cell lung cancer, both targeting mechanisms that differentiate them from existing treatments. With strong analyst support and upcoming clinical milestones, ORIC aims to capitalize on the increasing global demand for innovative cancer therapies.
2026-06-09 13:40:26
ORIC Pharmaceuticals is moving its rinzimetostat drug into a Phase III prostate cancer trial, having finalized the protocol and dosage. The drug has demonstrated competitive efficacy and a superior safety profile compared to rival treatments. Additionally, ORIC's enosertinib EGFR program shows strong CNS activity and safety, with further data expected. The company maintains a strong financial position, with cash reserves projected to last until late 2028.
2026-06-09 12:00:00
This article provides the transcript from Oric Pharmaceuticals Inc.'s presentation at the Goldman Sachs Healthcare Conference on June 9, 2026. Dominic Piscitelli, CFO of Oric Pharmaceuticals, discusses the recent discontinuation of Fulcrum's PRC2 inhibitor and its potential implications for Oric's Rinzimetostat program in prostate cancer. He notes that while Fulcrum's drug was being studied for sickle cell disease, the mechanism of action overlap is relevant to Oric's work.
2026-06-08 18:40:26
ORIC Pharmaceuticals Inc. (ORIC:NASDAQ) has granted 34,800 stock options and 5,900 restricted stock units to new non-executive employees hired in May 2026, as inducement grants under their 2022 Equity Incentive Plan. This move comes as analysts like Wedbush and H.C. Wainwright & Co. have reiterated "Buy" and "Outperform" ratings for ORIC, citing positive clinical trial results and a "catalyst-rich" year ahead for its oncology pipeline drugs, Rinzimetostat and Enozertinib. The grants emphasize the company's focus on growth within the expanding oncology treatment sector where innovation is crucial despite rising healthcare costs.
2026-06-06 18:40:34
ORIC Pharmaceuticals announced inducement grants to two new employees under Nasdaq Listing Rule 5635(c)(4). These grants, approved by the Compensation Committee, comprise stock options to purchase 32,500 shares of common stock. The options vest over four years and have an exercise price equal to the closing price of ORIC's common stock on May 28, 2024.
